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Abstract
There is an increasing medical need to detect and
spatially localize early and aggressive forms of prostate
cancer. Affinity ligands derived from bacteriophage
(phage) library screens can be developed to molecu-
larly target prostate cancer with fluorochromes for
optical imaging. Toward this goal, we used in vivo
phage display and a newly described micropanning
assay to select for phage that extravasate and bind
human PC-3 prostate carcinoma xenografts in severe
combined immune deficiency mice. One resulting
phage clone (G1) displaying the peptide sequence
IAGLATPGWSHWLAL was fluorescently labeled with
the near-infrared fluorophore AlexaFluor 680 and was
evaluated both in vitro and in vivo for its ability to bind
and target PC-3 prostate carcinomas. The fluorescently
labeled phage clone (G1) had a tumor-to-muscle ratio of
f30 in experiments. In addition, prostate tumors (PC-3)
were readily detectable by optical-imaging methods.
These results show proof of principle that disease-
specific library-derived fluorescent probes can be rap-
idly developed for use in the early detection of cancers
by optical means.
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Introduction
In the United States, the incidence of prostate cancer in
men is second only to that of skin cancer and accounts for
over 40,000 deaths annually [1]. Although there is evi-
dence that prostate-specific antigen screening can detect
early-stage prostate cancer, it is nonspecific and can miss
up to 30% of carcinomas [2]. Furthermore, markers for
distant prostate cancer metastases are needed. Recent
efforts have focused on identifying new prostate cancer–
specific cell surface antigens, receptors, and other locally
expressed biomarkers. Peptides, due to their ease of syn-
thesis, often ideal pharmacokinetic characteristics, and
nonimmunogenic nature, are attractive targeting agents
for the development of new prostate cancer imaging or
therapeutic agents.
The display of peptide libraries on the surface of bacterio-
phage (phage) offers a way of searching for peptides with spe-
cific binding properties. In vitro phage display has been used to
select peptides that target cancer-associated antigens [3,4],
whereas cultured carcinoma cells have also been employed to
isolate peptides that bind a variety of human carcinoma cell lines
[5–7]. In vivo phage display selection procedures offer an
advantage over in vitro screening protocols in that phage can
be selected based on desired pharmacokinetic properties, in-
cluding delivery and tumoral accumulation. Recently, in vivo
phage display has been explored as a means to identify phage
and corresponding peptides with optimal tumor-targeting prop-
erties in the context of living animals; however, many of these
peptides bind to endothelial cell markers but not directly to
tumor cells [8,9]. We believe that in vivo–selected phage can
serve as valuable first-line agents to determine if the phage
and corresponding synthesized peptides would function as effi-
cacious tumor-targeting and tumor-imaging agents.
Here, we report an in vivo phage display selection protocol
and a micropanning assay that allowed the identification of
novel prostate cancer– targeting peptides. Identified phage
clones were able to extravasate from the endothelium and to
specifically target prostate cancer cells in vivo. More precisely,
prostate tumor–avid phage was selected from a fUSE5
15-amino-acid peptide library [10] in severe combined immune
deficiency (SCID) mice bearing heterotransplanted human PC-
3 prostate tumors. An innovative ‘‘tumor-to-cell micropanning’’
assay was used to distinguish phage with high affinity for
prostate tumor tissues/heterotransplanted cell lines relative to
normal tissues and cell lines. A single-phage clonal population
with a high affinity for both prostate tumor tissues and PC-3
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carcinoma cell lines was fluorescently labeled with the near-
infrared fluorophore (NIRF) AlexaFluor 680 (AF680), and its
ability to bind prostate carcinomas, both in vitro and in vivo,
was analyzed. AF680-labeled phage were specific for PC-3
cells in vitro and allowed the successful noninvasive imaging
of prostate tumors in SCID mice.
Materials and Methods
Materials
Cell culture reagents were purchased from Invitrogen
(Carlsbad, CA). All other chemicals were purchased from
Sigma Chemical Co. (St. Louis, MO), unless otherwise
stated.
Cell Lines
PC-3 cells [11] were grown in Ham’s F12K medium, 7%
fetal bovine serum (FBS), 2 mM L-glutamine, and 48 mg/ml
gentamicin at 37jC in 5% CO2. Human embryonic kidney
(HEK) 293 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM)–high glucose with 10% heat-inactivated
FBS, 2mM L-glutamine, 1mM sodium pyruvate, and 48 mg/ml
gentamicin at 37jC in 5%CO2. All other cell lines were grown
in a general maintenance medium containing RPMI 1640
(custom) with 10% FBS and 48 mg/ml gentamicin. The cell
lines were tested for pathogens before injection into mice.
Mouse Strains and Handling
Four- to 6-week-old (approximately 20 g) ICRSC-M SCID
outbred mice were obtained from Taconic (Germantown, NY)
and maintained in an approved pathogen-free institutional
housing. Animal studies were conducted as outlined in the
NIH Guidelines for the Care and Use of Laboratory Animals
and the Policy and Procedures for Animal Research of the
Harry S. Truman Veterans Memorial Hospital and the Mas-
sachusetts General Hospital. Solid tumors were established
in SCID mice over a period of 4 weeks, resulting in mice
with appropriately 1-cm–sized tumors for all experiments.
PC-3 prostate carcinoma cells (5  106) were injected sub-
cutaneously in one flank of each anesthetized animal.
Tumors generally appeared in 30 days. Following in vivo
selection or biodistribution, the mice were euthanized, and
tumors and organs were excised from the animals and
handled as described in later sections.
In Vivo Selection of Tumor-Targeting Phage
A fUSE5 phage display library, which displayed random
15 amino acid peptides on coat protein III, was a gift from
Dr. George Smith [10]. Library amplification was conducted
as described previously [12]. The phage particle concentra-
tion, in virions (V), was determined spectrophotometrically,
and the amount of infectious units (transducing units, TU)
was determined by titering on Escherichia coli K91 Blue Kan.
About 1012 TU of a 15-amino-acid fUSE5 library sus-
pended in phosphate-buffered saline (PBS) was injected
into the tail vein of normal non–tumor-bearing CF-1 mice
for 15 minutes to preclear phage that bound to the normal
vasculature and other nontumor antigens [13]. Themicewere
then anesthetized, and blood (f3 ml) was obtained. Phage
were isolated from the blood by polyethylene glycol (PEG)
precipitation, amplified, purified, and dialyzed, as described
previously [12]. Next, 1012 TU of the precleared phage library
was injected into SCID mice bearing PC-3 human prostate
cancer cell xenografts. After 1 hour of in vivo phage circu-
lation, the mice were sacrificed by cervical dislocation. The
animals were perfused with 90 ml of PBS to facilitate phage
elimination from the vasculature, and organs and tumors
were removed, weighed, and quick-frozen in liquid nitrogen.
Prostate tumors were ground in DMEM with protease inhib-
itors (1 mM phenylmethylsulfonyl fluoride, 20 mg/ml aprotinin,
and 1 mg/ml leupeptin) and 0.5%bovine serumalbumin (BSA)
(DMPB) and washed thrice by centrifugation at 6000 rpm.
Pelleted lysate was resuspended in DMPB + 2.5%CHAPS to
recover extravasated phage, and the recovered phage pop-
ulation was used to infect fresh E. coli K91 Blue Kan host
cells. A portion of purified phage preparation (in PBS) was
used as the input phage for the next round of in vivo selection.
In total, four rounds of selection were performed. Between
rounds, foreign DNA inserts and encoded peptide sequences
were determined for 10 random phage clones to gauge the
selection process and the absence of contamination. The
amino acid sequences of displayed peptides were deduced
from the DNA sequence. Sequences from selections were
compared using Align, PIR, NiceBlast, gapped, and PSI-
BLAST search databases [14,15] to identify the presence of
consensus motifs or potential tumor targets and to define
clones for further analyses.
Micropanning Assay
A newly described multistep ‘‘micropanning’’ assay was
devised to quickly and efficiently identify clones that specif-
ically recognized PC-3 tumor tissues and PC-3 human pros-
tate carcinoma cells and, thus, had potential in in vivo PC-3
tumor targeting. In the first tier of micropanning, 1.5 107 TU
of in vivo–selected phage clones was incubated at 4jC for
2 hours with excised normal muscle tissues or PC-3 tumor
tissues. The tissues were then washed five times with DMPB,
and bound phage were eluted from the tissues using DMPB +
2.5% CHAPS. The ratio of phage titer in tumor tissues to
phage titer in normal tissueswas calculated. In vivo–selected
phage clones that recognized tumor tissues with a 1.5-fold
specificity over normal tissues were assumed to have suffi-
cient affinity and specificity for prostate tumor cells to warrant
further investigation. In the second tier of the assay, phage
that specifically bound to cultured PC-3 cells versus a non-
relevant control cell line were identified. Nine phage clones
identified in the first tier were incubated (similar to the first
tier) with either intact PC-3 prostate carcinoma cells or non-
relevant control cells (HEK293). Bound phage were eluted
with DMPB + 2.5% CHAPS, and the ratio of phage titer in
PC-3 cells to phage titer in HEK293 cells was calculated.
Conjugation of AF680 to Phage
An AF680 carboxylic acid, succinimidyl ester 5-isomer
(Invitrogen), was dissolved in dimethyl sulfoxide and added
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to a suspension of phage in 1 coupling buffer (0.5 M Na3
citrate, 0.1 M NaHCO3, pH adjusted to 8.5 with NaOH) at a
1:1 molar ratio of AF680/coat protein VIII (1% dimethyl
sulfoxide, final concentration). This mixture was then incu-
bated at room temperature for 4 hours in the dark. Sub-
sequently, ethanolamine at 150 mM (pH adjusted to 9.0 with
HCl) was added for 2 hours in the dark at room temperature.
The samples were then PEG-precipitated twice and dialyzed
extensively against 50 mM Tris–HCl and 150 mM NaCl
(pH 7.5; TBS) to remove excess hydrolyzed AF680.
Determination of the Binding of AF680-Labeled Phage
to PC-3 Cells by Modified Enzyme-Linked Immunosorbent
Assay (ELISA)
PC-3 carcinoma cells were grown tof90% confluency in
a tissue culture–treated 96-well plate (TPP, Trasadingen,
Switzerland). The growthmedium (previously described) was
removed, and a new complete medium with the appropriate
concentration (5  109 to 1  1011 V/ml) of AF680-labeled
phage or unlabeled phage was added to the wells. The plate
was incubated at 37jC for 1.5 hours then washed with ice-
cold PBS for a number of times. Cells and bound phage were
then fixed to the plate by the addition of PBS with 4%
formaldehyde. The presence of phage was then probed by
the addition of a rabbit polyclonal anti-phage antibody (cour-
tesy of Dr. George Smith). The plate was then incubated at
room temperature for 1 hour and extensively washed with
TBS. A secondary anti-rabbit antibody conjugated to horse-
radish peroxidase (Santa Cruz Biotechnology, Santa Cruz,
CA) was added and incubated at room temperature for
1 hour. The plate was washed with TBS + 1% Tween, and
liquid peroxidase substrate [2,2-azino-bis(3-ethylbenzothia-
zoline-6-sulfonic acid] was added and incubated for 10 min-
utes at room temperature. The addition of 1%sodiumdodecyl
sulfate was used to stop the reaction. The plate was then
read on a m Quant Universal Microplate Spectrophotometer
(Bio-Tek Instruments, Winooski, VT) at an absorbance of
405 nm using an endpoint assay.
Confocal Microscopy for the Determination of Cell
Surface Binding
The binding of the AF680-labeled phage to PC-3, PC-3M,
LNCaP, DU145, RPWE-1, MDA-MB-435, and HEK293 cells
was determined using laser scanning confocal microscopy,
as described previously [16]. Cells (1  104) were dried on a
microscope slide and blocked with 6% BSA in 10 mM Tris.
The slides were incubated with wild-type (WT) or G1-phage
solutions (1  1011 V/ml phage in 10 mM Tris, pH 7.5, 1%
BSA) at room temperature for 1 hour in the dark. A com-
parison of AF680 phage binding and biotinylated peptide
binding to PC-3 carcinoma cells and HEK cells was also
conducted using laser scanning confocal microscopy. The
binding of biotinylated peptide (G1 and scrambled G1) was
detected using 10 mg/ml NeutrAvidin–Texas Red (Molecular
Probes, Eugene, OR; incubation at room temperature for
30 minutes in the dark). Laser scanning confocal microscopy
was performed on a Bio-Rad Laboratories (Hercules, CA)
MRC 600 confocal microscope (University of Missouri Mo-
lecular Cytology Core Facility).
Biodistribution of AF680-Labeled Phage
AF680-labeled phage (f109 TU) were injected intrave-
nously into SCID mice bearing PC-3 prostate cancer cell
xenografts. The mice were sacrificed at 5 minutes, 30 min-
utes, 2 hours, 4 hours, 6 hours, and 24 hours after injection.
Mice were perfused with 90 ml of PBS, and organs and
tumors were removed and quick-frozen in liquid nitrogen.
Organs and tumors were ground in TBS buffer, and the
amount of protein in each tissue homogenate was then de-
termined using the Bio-Rad Protein Assay (Bio-Rad Labo-
ratories). Tissue homogenates at 5 mg/ml protein were
analyzed for fluorescent activity at appropriate wave-
lengths, using an IVIS 200 fluorescence reflectance imaging
system (Xenogen Corp., Alameda, CA). To account for auto-
fluorescence, organs from SCID mice that had been injected
with only PBS were also collected and homogenized, and
fluorescence was measured. The autofluorescence of each
organ homogenate was then subtracted from experimental
organ homogenates.
The presence of the phage particle’s coat protein VIII
within tissue homogenates was confirmed using immuno-
blotting. Tissue homogenates at a concentration of 5 mg/ml
crude protein were electrophoresed on 16% Tricine gels and
transferred to nitrocellulose membranes. Coat protein VIII
was detected by incubating the membrane with a rabbit
polyclonal anti–coat protein VIII phage antibody at room
temperature for 2 hours, and then by extensive washing with
TBS + 1% Tween. A goat anti-rabbit antibody conjugated to
horseradish peroxidase was added and allowed to incubate
at room temperature for 2 hours. Themembranewas washed
with TBS + 1% Tween, and chemiluminescent peroxidase
substrate (SuperSignal West Pico; Pierce, Rockford, IL) was
added then exposed to autorad film and developed.
Imaging of PC-3 Xenografted Tumors
Male SCID mice implanted with PC-3 cells, as outlined
above, were chemically depilated over lesions 24 hours
before in vivo imaging to minimize autofluorescence and to
maximize signals. A fluorescence reflectance image was ob-
tained before and after (immediately, 1, 4, and 24 hours) the
intravenous injection of 109 TU of phage. Fluorescence re-
flectance imaging was performed using a bonSAI system
(Siemens Medical, Erlangen, Germany) with the animals
under gas anesthesia. Fluorescence signals were measured
using ImageJ software (NIH, Bethesda, MD), choosing con-
sistent exposure times. Tumors were resected for histo-
pathology directly after the last time point.
Results
A 15-amino-acid fUSE5 phage display library precleared of
phage clones that bound to organs and vasculature antigens
in normal CF-1 mice was amplified and used as input phage
for the in vivo selection of PC-3 prostate tumor binding phage.
After four rounds of successive in vivo selection, 96 phage
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clones were sequenced and compared to our laboratory’s
phage–peptide sequence database (data not shown). When
compared to our database, 19 clones were found to be
unique and were thus further pursued. Align, PIR, NiceBlast,
gapped, and PSI-BLASTsearch algorithms were used to an-
alyze foreign amino acid sequence inserts of the 19 clones;
however, no significant similarities to other proteins were
found [14,15]. The 19 clones were analyzed for specificity
using a two-tier micropanning procedure. In the first tier of the
assay, phage were micropanned against PC-3–derived
tumor tissues and normal muscle tissues. Nine phage clones
generated a tumor-to-muscle specificity ratio of z 1.5 and
were carried forward to be analyzed in the next stage of
micropanning. The second tier of micropanning was used to
select phage clones that bound preferentially to in vitro–
cultured PC-3 tumor cells. Of the nine phage clones carried
forward from the first tier of micropanning, two (D9 and
E8) did not bind at all to cultured PC-3 cells, six had a ratio
of < 1.0 (D4, D7, F1, F6, F12, and G8), and only one (G1:
IAGLATPGWSHWLAL) had a ratio of > 2 (Table 1). The G1
phage produced a signal-to-noise ratio of > 1.5 in the first
tier of micropanning and yielded the highest ratio in the
second tier of micropanning, demonstrating the specificity
of binding to PC-3–derived tumors and in vitro–cultured
prostate carcinoma cells. Therefore, G1 was chosen for fur-
ther characterization.
To directly detect phage and to explore their use in cancer
detection, G1 and WT phage were labeled with AF680 at an
average of f600 AF680 molecules per phage particle. A
modified ELISA was employed to investigate the effect of
AF680 labeling on phage affinity for cultured PC-3 prostate
carcinoma cells (Figure 1). The presence of AF680 on the
surface of phage led to no significant change in the binding
of G1 or WT phage to cultured PC-3 prostate carcinoma
cells. At phage concentrations between 5.0 1010 and 1.0
1011 V/ml, AF680 G1 phage exhibited a f3-fold increase
in binding to PC-3 carcinoma cells compared to AF680 WT
phage (Figure 1).
The binding patterns of NIRF-labeled phage were com-
pared to those of free peptides to ensure that the binding
properties of G1 phage were due to the presence of the
peptide and not to potential inherent nonspecific binding of
fd phage particles [17,18]. Laser scanning confocal micros-
copy was used to investigate and compare the binding of
biotinylated free peptides and peptides displayed on AF680-
labeled phage particles (Figure 2A). AF680-labeled G1
phage and biotinylated free G1 peptides both displayed high
intensity, cell membrane–associated binding to cultured
PC-3 cells, and little to no binding to HEK293 cells, demon-
strating the specificity of the G1 peptide to PC-3 cells. In
contrast, AF680-labeled WT phage and biotinylated free
control peptides resulted in no significant binding to either
cultured PC-3 or HEK293 cells. The specificity of binding of
AF680-labeled G1 phage to other cultured cells was further
investigated using confocal microscopy. It was found that
AF680 G1 phage bound to the prostate carcinoma cell lines
PC-3, PC-3M (highly metastatic subline derived from PC-3),
Figure 1. Binding of AF680-labeled phage and unlabeled phage to PC-3
human prostate carcinoma cells. PC-3 human prostate carcinoma cells were
grown to 90%confluency in a 96-well plate. Phageat 5 109, 1 1010, 5 1010,
or 1 1011 V/ml were added to wells containing a complete growthmedium and
were allowed to incubate for 1.5 hours at 37jC. Cells and attached phage were
then washed with ice-cold PBS and fixed with 4% formaldehyde. The presence
of phage was detected by a rabbit polyclonal anti-phage antibody, followed
by an anti-rabbit antibody conjugated to horseradish peroxidase. Liquid
peroxidase substrate was added, and the plate was then read on a  Quant
Universal Microplate Spectrophotometer at an absorbance of 405 nm.
Table 1. Two-Step Phage Micropanning Assay to Evaluate the Specificity of Selected Phage Clones.
Clone No. Sequence First Round Second Round
Normal Tissue Tumor Tissue Ratio HEK Cells PC-3 Cells Ratio
D4 GTRQGHTMRLGVSDG 21,000 315,000 15.00 108,000 96,000 0.89
D7 GDVWLFKTSTSHFAR 24,000 300,000 12.50 480,000 66,000 0.14
D9 LWVFPAGGHLGRERS 39,000 270,000 6.92 NT NT
E8 VMVPYSVRDSLFGSF 75,000 156,000 2.08 NT NT
F1 SVGGWFRQHLVGTRM 1,200 6,000 5.00 2,400 1,500 0.63
F6 LASIVRWEQVPDALS 12,000 21,000 1.75 5,400 300 0.06
F12 SGVWAPTAGYDAGFH 13,500 27,000 2.00 7,800 5,100 0.65
G1 IAGLATPGWSHWLAL 10,800 18,000 1.67 8,400 18,000 2.14
G8 SHSDYRPAPWSGWML 600 2,400 4.00 2,700 2,400 0.89
Phage collected from in vivo phage display selections were screened for specificity of binding to both PC-3–derived tumor tissues and cultured PC-3 human
carcinoma cells. In the first round of micropanning, phage were incubated with either excised normal muscle tissues or PC-3 tumor tissues. Bound phage were then
eluted from tissues by incubation in DMPB + 2.5% CHAPS for 1 hour at 4jC. The amount of eluted phage was then determined by phage titer, and the tumor-
tissue-to-normal-tissue ratio was then calculated. All phage clones with a ratio of z 1.5 were then used in a second round of micropanning with cultured cell lines.
Phage were incubated with cultured HEK293 cells (nonrelevant control) or cultured PC-3 human carcinoma cells. Bound phage were again eluted and titered, and
the cultured PC-3 cells/HEK293 cells ratio was calculated.
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LNCaP (lymph node metastasis), and DU145 (derived from
brain metastasis) (Figure 2B). AF680 G1 phage bound with
highest intensity to PC-3 cells and with slightly reduced
intensity to the other human prostate carcinoma cell lines
tested. Little to no binding of AF680 G1 phage to RPWE-1 (a
normal human prostate cell line), MB-MDA-435 (a human
breast carcinoma cell line), and HEK293 cells was observed.
Micropanning data for these seven cell lines were consis-
tent with these results (data not shown). These data dem-
onstrate that the binding of the G1 phage is due to the
presence of the G1 peptide and that the peptide is specific
for prostate carcinomas.
To determine the in vivo distribution of the G1-phage
clone, we injected AF680-labeled G1 phage into SCID mice
bearing subcutaneously implanted PC-3 cell–derived tumors
(Figure 3A). Both the AF680 G1 phage and the WT phage
cleared through the organs of the reticuloendothelial system
(RES), such as the liver, lungs, and kidneys (Figure 3, A and
B). AF680 phage began to amass in the RES in as early as
5 minutes and continued at 6 hours. Muscle, fat, brain, and
spleen exhibited very low levels of fluorescence. The accu-
mulation of AF680 G1 phage in the tumor began as early as
5 minutes and peaked from 4 to 6 hours. The tumor-to-fat-
uptake ratio for AF680 G1 phage was f10 at 4 hours
postinjection, in contrast to f3 for AF680 WT phage. The
tumor-to-muscle-uptake ratio for AF680 G1 phage wasf30
between 30 minutes and 6 hours postinjection. In contrast,
the tumor-to-muscle-uptake ratio for WT phage wasf11 at
5 minutes postinjection and diminished to f8 by 6 hours
postinjection. Notably, AF680-labeled G1 phage yielded a
73% higher mean in tumor fluorescence over that of AF680-
labeled WT phage at 4 hours postinjection. These data
provide evidence for the binding of G1 phage to xenografted
PC-3 tumors in SCID mice.
The presence of phage particles in tissue homogenates
was verified by immunoblotting (Figure 4A). Immunoblots
demonstrated the presence of phage in the liver as well as
in the tumor, confirming biodistribution results and the fluo-
rescent distribution of AF680 (Figure 4B). These findings
support the results of the fluorescent biodistribution studies
of AF680 and indicate that the intensity of the AF680 fluo-
rescent signal measured corresponds to the presence of
phage in tissues and organs. Furthermore, phage isolated
from liver and tumor extracts by PEG precipitation were
spectrophotometrically scanned from 600 to 800 nm (for
AF680) and from 240 to 320 nm (for phage particles),
demonstrating that fluorescence and phage particles co-
precipitated (data not shown). Taken together, these data
Figure 2. Binding of AF680-labeled phage and peptides to human carcinoma cells and control normal cells. Slides containing fixed PC-3 or HEK293 cells were
incubated with AF680-labeled phage solutions (1 1011 V/ml phage in 10 mM Tris, pH 7.5, 1% BSA) or biotinylated peptide solutions (20 M peptide in 10 mM Tris,
pH 7.5, 1% BSA) at room temperature for 1 hour in the dark. The binding of biotinylated peptides was detected using 10 g/ml NeutrAvidin –Texas Red (A).
Specificity of binding was determined by incubating AF680 G1 or WT phage on slides containing PC-3, PC-3M, LNCaP, DU145, RPWE-1, MB-MDA-435, and
HEK293 cells (B). The presence of fluorophore was detected by laser scanning confocal microscopy.
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suggest that AF680-labeled G1 phage are stable in vivo and,
as such, could easily be used as an in vivo imaging agent.
To explore the usefulness of G1 phage as an in vivo
imaging agent, we performed surface reflectance imaging
with AF680-labeled G1 phage. AF680-labeled phage could
be imaged in PC-3–derived tumors in SCID mice as early as
1 hour postinjection (Figure 5). The peak of signal intensity
and specificity within the tumor occurred at 4 hours post-
injection, consistent with the distribution data presented in
Figure 3. At 4 hours postinjection of AF680 G1 phage, a
4.5-fold increase in the fluorescent signal within the tumor
compared to that of the normal tissue was observed with a
specificity of 2.1-fold (G1-to-WT phage tumoral accumula-
tion). Together, these data confirm that the G1 peptide dis-
played on the tip of coat protein III has a direct influence on
the extravasation, accumulation, and retention of AF680-
labeled phage within the tumor and that this sequence is
specific for prostate tumors.
Discussion
We selected in vivo phage that target human PC-3 prostate
carcinomas heterotransplanted in SCID mice. The phage
clone G1 displaying the peptide sequence IAGLATPGWS-
HWLAL bound both cultured PC-3 carcinoma cells in vitro
and PC-3 tumors ex vivo. More importantly, fluorescently
labeled versions of the phage resulted in increased signal
intensity within PC-3 xenografted tumors in SCID mice.
These results provide proof of principle that fd filamentous
phage can indeed be used for the in vivo selection of
extravasating phage that specifically target cancer cells,
which can be fluorescently labeled for use as a noninvasive
tumor-imaging tool.
Selection of extravasating phage that bound tumor cells
was accomplished by first preclearing the 15-amino-acid
fUSE5 phage display library in normal mice so as to remove
unwanted phage that bound organs and normal vasculature
components. The preselected library was incubated in tumor-
Figure 3. Biodistribution of AF680-labeled G1 fUSE5 and WT phage in PC-3 xenografted SCID mice. SCID mice bearing human PC-3 carcinoma tumors were
injected withf109 TU of AF680-labeled G1 fUSE5 phage (A) and AF680-labeled WT phage (B) and were allowed to circulate for 5 minutes, 30 minutes, 2 hours,
4 hours, and 6 hours. Organs were excised, homogenized, and probed for fluorescent activity using the Xenogen IVIS 200 system.
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bearing mice for times sufficient for extravasation to occur
[13]. From this in vivo selection, the peptide inserts of
96 phage clones were determined and compared to our la-
boratory’s database of phage-displayed peptide sequences.
Only 19 clones were unique to this particular phage display
selection, supporting the notion that phage display proce-
dures often result in ‘‘winning’’ clones that may be obtained
due to inherent undesirable properties such as high infec-
tivity, good growth capabilities, or hydrophobic nonspecific
binding properties [18]. A two-tiered micropanning assay
was designed to identify which, if any, of the 19 clones had
preferential affinity for both PC-3 prostate tumors and PC-3–
cultured carcinoma cells. Because fd phage often exhibit
nonspecific binding [17,18], the first tier of micropanning
was used as an indication of the level of background noise
(binding of phage to normal tissues), as well as the ability of
the phage to specifically bind tumor tissues. However, a
positive finding in such an assay does not guarantee the
binding of phage to actual tumor cells because tumor tissues
are obviously composed of tumor cells (in addition to con-
nective tissues) and extracellular matrix components. The
second tier of micropanning was then used as an indication
of whether the selected phage bound to PC-3 cells them-
selves or bound normal cells such as HEK293 kidney cells.
The ratio of the binding of PC-3 cells to HEK293 was
calculated, and only one clone (G1) had a ratio of > 2 and
was thus further investigated.
In vitro characterization of AF680 G1-phage binding prop-
erties, compared to that of AF680WT, included both modified
ELISA and confocal microscopy. These assays provided
proof of AF680-labeled G1-phage binding to cultured PC-3
cells in vitro. G1 sequence was not specific for PC-3 cells in
that binding to other human prostate cancer cells was ob-
served. Importantly, confocal microscopy indicated that G1
phage bound with much higher affinity to cultured human
prostate carcinoma cells than to RPWE-1 normal prostate,
MB-MDA-435 breast carcinoma, or HEK293 embryonic kid-
ney cell lines. Thus, the G1 sequence may target a pros-
tate cancer–specific antigen. The very low background of
AF680WTphage observed in confocalmicroscopy (Figure 2)
was likely due to the fact that cultured cells were prefixed
Figure 4. Biodistribution of AF680-labeled G1 fUSE5 and WT phage in PC-3
xenografted SCID mice. Homogenized tissues from SCID mice bearing
human PC-3 carcinoma tumors were probed for the fluorescent activity of
AF680 label and for the presence of coat protein VIII. The presence of the
phage coat protein VIII was verified by the immunoblotting of tumors, livers,
fats, and muscles (A). Homogenized tissues were electrophoresed on 16%
Tricine gels and transferred to 0.45-m nitrocellulose membranes. Coat
protein VIII was detected by incubating the membrane with a rabbit polyclonal
anti – coat protein VIII phage antibody followed by a goat anti-rabbit antibody
conjugated to horseradish peroxidase. Signal was determined by the addition
of chemiluminescent peroxidase substrate, exposure to double-emulsion
Blue Lite autorad film, and development of the film using Kodak (Rochester,
NY) processing chemicals. Homogenized tumors, livers, fats, and muscles
were probed for fluorescent activity using the Xenogen IVIS 200 system (B).
Figure 5. In vivo imaging of a PC-3 prostate tumor using AF680-labeled G1 fUSE5 phage. SCID mice bearing PC-3 tumors were injected with AF680-labeled G1 or
WT phage. Fluorescence reflectance images of anesthetized mice were obtained 0 minute, 1 hour, 4 hours, and 24 hours postinjection (A). Fluorescence signals of
normal and tumor tissues were quantified using ImageJ software (B).
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with formaldehyde and, therefore, could be washed much
more vigorously than live cells used for micropanning and
modified ELISA. Both in vitro assays with AF680 G1 phage
exhibited a V three-fold increase in signal from AF680 G1
over that of AF680 WT.
In vivo characterization of the AF680 G1 phage included
biodistribution studies as well as optical imaging. Biodistribu-
tion of AF680-labeled G1 andWT phage in PC-3 xenografted
SCID mice exhibited similar distribution and clearance pro-
files. The muscle-to-tumor ratio found in in vivo distribution
was much higher than that found in the micropanning as-
say. This is most likely due to the inability of large phage
particles to extravasate in vivo into muscle tissues, which
maintain very tight junctions between endothelial cells. In
comparison, the micropanning assay involves the incuba-
tion of a large concentration of phage within homogenized
tissues, thus allowing the characteristic nonspecific binding
of phage. Another reason for the difference of muscle-to-
tumor ratios found with micropanning versus in vivo biodis-
tribution was the stringency of the micropanning assay.
Micropanning experiments used very stringent washing and
detergent elution techniques. Additional micropanning ex-
periments using amore traditional acid elution [12] generated
a recovered-phage-from-PC-3-to-recovered-phage-from-
HEK293 ratio of 5, compared to that of 2.14 from the more
stringent CHAPS detergent elution. Thus, the technique used
within micropanning experiments has a direct impact on the
number and type of phage recovered from tissues or cell
pellets. The high background binding found for WT phage in
in vitro assays is not unexpected, as phage are well known
to bind to various supports such as plastic [19]. Our goal was
not to reduce nonspecific in vitro binding but to find phage
that extravasated and targeted tumors in vivo. The G1 phage
had a tumor-to-muscle ratio of 30 in vivo, suggesting that
high backgrounds in vitro do not necessarily correlate with
in vivo tumor targeting.
In view of biodistribution data, we observed the clearance
of phage particles through the RES, which is consistent with
previous observations from our laboratory [13] and others
[20,21]. It was found in the distribution studies that AF680-
labeled G1 phage accumulated and bound to human pros-
tate PC-3 tumors in vivo with a 73% higher mean over that
of AF680-labeled WT phage. In vivo surface reflectance
imaging with AF680 G1 phage resulted in a two-fold increase
over the background signal from AF680-labeled WT phage.
Both of these findings are in agreement with results from
in vitro assays.
G1 phage and the corresponding peptide demonstrated
preferential binding to human prostate carcinoma cell lines. In
an effort to identify the targeted antigen, protein search
algorithms were employed; however, no significant homolo-
gies to G1 were found. This result is not surprising in that only
a handful of antigens targeted by in vivo–selected peptides
have been identified [18,22,23]. The majority of peptides
targeted integrins through RGD-like or similar peptide motifs
[9,23]. Furthermore, affinity chromatography experiments
using the G1 sequence with extracts of cultured prostate
cancer cell lines did not yield a candidate protein antigen
(data not shown). Taken together, these results suggest that
the target of G1may be a sparse protein antigen or a complex
antigen consisting of protein, lipid, and/or carbohydrate com-
ponents [24]. Our findings further support the idea that in vivo
selection of phage can be used to target rare and unique
biomarkers on cancer cells, notmerely vascular components.
The use of labeled phage as an alternative to labeled
peptides for the screening of tumor-targeting agents has
several advantages. The first and foremost advantages are
affordability and speed, because the synthesis and labeling of
multiple peptides are a more costly and lengthy procedure.
The screening of phage particles allows for more flexibility
than the screening of peptides. The initial screening of phage
displaying selected peptides can be accomplished biologi-
cally by tracking the phage spectrophotometrically or by
titering on host E. coli, whereas peptides must be tagged.
The addition of fluorophores, radiochelators, and epitope
tags can have negative effects on the binding properties of
peptides [25]. Hence, implementation of peptides displayed
on phage may be a useful gauge of the ability of synthesized
peptides to bind to their target before laborious peptide modi-
fications ensue.
Because phage are organic and nonpathogenic [20,21],
they may be thought of as multifunctional self-replicating
biologic nanoparticles [26] in that they can be covalently
attached to numerous tags or labels while simultaneously
expressing multiple copies of foreign peptides. The resulting
signal amplification is of enormous benefit to the peptide
screening process and may expedite the discovery and
characterization of a ‘‘dark horse’’ peptide without the docu-
mented side effects of other nanoparticles with metallic cores
(such as cadmium–selenium or other metals) [27–30]. Sig-
nal amplification is also beneficial to the characterization of
phage displaying peptides in in vivo models of diseases
such as cancer. It allows for a quick and easy characteriza-
tion of the distribution profile of peptides. As phage have
their own distinct in vivo distribution, the peptide-bearing
phage would need to be compared to phage particles with
no displayed peptides. In general, the use of phage as self-
replicating bionanoparticles is a very safe, simple, and at-
tractive solution for the development and implementation of
new prostate screening modalities.
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